Literature DB >> 15907255

Treatment of painful polyneuropathies.

Bruce Nicholson1.   

Abstract

The treatment of painful polyneuropathies has begun to improve over the past several years. This is based on an evolving understanding of the pathogenesis related to the development of diabetic neuropathy and other diseases that may lead to peripheral nerve injury. Consensus on evaluation strategies for patients presenting with pain has furthered our ability to define neuropathic pain and accompanying signs and symptoms that may respond to particular therapeutic approaches. Recent therapeutic advances in medical management have demonstrated improved outcomes in pain relief. This, along with lower side effect-related issues, has led to improved compliance and patient satisfaction. The assessment and treatment of comorbid conditions, which include sleep, anxiety, and depression, have further advanced the management of painful polyneuropathies in patients. New antiepileptics, antidepressants, and topical therapies have contributed to improved patient outcomes.

Entities:  

Mesh:

Year:  2005        PMID: 15907255     DOI: 10.1007/s11916-005-0059-7

Source DB:  PubMed          Journal:  Curr Pain Headache Rep        ISSN: 1534-3081


  44 in total

Review 1.  Antidepressants and anticonvulsants for diabetic neuropathy and postherpetic neuralgia: a quantitative systematic review.

Authors:  S L Collins; R A Moore; P Wiffen
Journal:  J Pain Symptom Manage       Date:  2000-12       Impact factor: 3.612

2.  Venlafaxine versus imipramine in painful polyneuropathy: a randomized, controlled trial.

Authors:  S H Sindrup; F W Bach; C Madsen; L F Gram; T S Jensen
Journal:  Neurology       Date:  2003-04-22       Impact factor: 9.910

Review 3.  Efficacy of pharmacological treatments of neuropathic pain: an update and effect related to mechanism of drug action.

Authors:  Søren H Sindrup; Troels S Jensen
Journal:  Pain       Date:  1999-12       Impact factor: 6.961

4.  A pilot study of the beneficial effects of amantadine in the treatment of painful diabetic peripheral neuropathy.

Authors:  P Amin; N D C Sturrock
Journal:  Diabet Med       Date:  2003-02       Impact factor: 4.359

Review 5.  Pregabalin: in the treatment of painful diabetic peripheral neuropathy.

Authors:  James E Frampton; Lesley J Scott
Journal:  Drugs       Date:  2004       Impact factor: 9.546

6.  Pregabalin and gabapentin reduce release of substance P and CGRP from rat spinal tissues only after inflammation or activation of protein kinase C.

Authors:  Jill C Fehrenbacher; Charles P Taylor; Michael R Vasko
Journal:  Pain       Date:  2003-09       Impact factor: 6.961

7.  Controlled-release oxycodone relieves neuropathic pain: a randomized controlled trial in painful diabetic neuropathy.

Authors:  C Peter N Watson; Dwight Moulin; Judith Watt-Watson; Allan Gordon; John Eisenhoffer
Journal:  Pain       Date:  2003-09       Impact factor: 6.961

8.  EFNS guidelines on neuropathic pain assessment.

Authors:  G Cruccu; P Anand; N Attal; L Garcia-Larrea; M Haanpää; E Jørum; J Serra; T S Jensen
Journal:  Eur J Neurol       Date:  2004-03       Impact factor: 6.089

9.  Aldose reductase inhibition by AS-3201 in sural nerve from patients with diabetic sensorimotor polyneuropathy.

Authors:  Vera Bril; Robert A Buchanan
Journal:  Diabetes Care       Date:  2004-10       Impact factor: 19.112

10.  Thermal thresholds predict painfulness of diabetic neuropathies.

Authors:  Heidrun H Krämer; Roman Rolke; Andreas Bickel; Frank Birklein
Journal:  Diabetes Care       Date:  2004-10       Impact factor: 19.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.